Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Find out the media information related to Oncodesign
Philippe Genne | Chairman and CEO
After gaining a PhD in pharmacology from the University of Dijon, Philippe Genne began his scientific career as a project leader at Debiopharm where he oversaw a clinical development program related to multi-drug resistance inhibitors. He also worked as a research associate at Glaxo-Welcome.
His preclinical research experience in oncology also encompasses phase I and phase II clinical trials in conjunction with Inserm. In 1995, he founded Oncodesign in Dijon. Over the past 18 years, he has earned a reputation as a serial entrepreneur in life sciences. As well as being Chairman of Oncodesign, a company specialized in the discovery of new therapies and European leader in the preclinical evaluation of anti-cancer therapies, he is also Chairman of the Pharmimage platform, which he set up in 2008. Philippe Genne is well known for his activities right across the life sciences value chain. In 2012, he helped set up the French association of life sciences service and innovation companies (AFSSI). He is the Vice-President of the SMEs College at Medicen.
Oncodesign Boiler Plate
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 230 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.
Oncodesign Philippe Genne | CEO Tel. : +33 (0)380 788 260